Reuters logo
BRIEF-Kalytera Therapeutics Says ‍Results Of Phase 2 Clinical Study In Prevention Of Graft Versus Host Disease​ Are Expected By Q3 2018
December 7, 2017 / 1:45 PM / 6 days ago

BRIEF-Kalytera Therapeutics Says ‍Results Of Phase 2 Clinical Study In Prevention Of Graft Versus Host Disease​ Are Expected By Q3 2018

Dec 7 (Reuters) - Kalytera Therapeutics Inc:

* KALYTERA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PREVENTION OF GRAFT VERSUS HOST DISEASE AND AGREEMENT WITH THE SALZMAN GROUP OF ISRAEL TO MANAGE AND PARTIALLY FUND THE STUDY TO BE LED BY A WORLD CLASS TEAM

* KALYTERA THERAPEUTICS INC - ‍RESULTS OF PHASE 2 CLINICAL STUDY IN PREVENTION OF GRAFT VERSUS HOST DISEASE​ ARE EXPECTED BY Q3 2018

* KALYTERA THERAPEUTICS INC - ‍ANTICIPATES THAT, FOLLOWING COMPLETION OF PHASE 2 STUDY, IT WILL INITIATE PHASE 3 STUDY “AS QUICKLY AS POSSIBLE”​

* KALYTERA - ‍ENTERED AGREEMENT WITH SALZMAN GROUP, UNDER WHICH SALZMAN GROUP TO PROVIDE CLINICAL STUDY MANAGEMENT SERVICES IN RELATION TO PHASE 2 STUDY​

* KALYTERA THERAPEUTICS INC - ‍ESTIMATED COST OF SERVICES TO BE PROVIDED BY SALZMAN IS EXPECTED TO BE APPROXIMATELY $1.2 MILLION OVER AN 11-MONTH PERIOD​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below